At America AACR, announces poster
of preclinical
results of EGFR Exone
20 insertion mutant lung cancer
treatment TRX-211-399

4th generation non-small cell lung cancer

targeted anti-cancer drug TRX-221 Ministry of Food

and Drug Safety approves phaes 1 clinical trial

At Spain ESMO, announces poster
of results preclinical follow-up study

of TRX-221 targeted anti-cancer
drugs for non-small cell lung cancer

4th generation non-small cell lung
cancer targeted anti-cancer drug

TRX-221 U.S. FDA approves phase
1 clinical trial

At America AACR, announces poster
of preclinical results of 4th

generation non-small cell lung
cancer candidate material TRX-221

Holding the 1st clinical advisory
committee in 4th generation
non-
small cell lung cancer therapeutics
candidate material TRX-221

MOU Concluding on development of
new anti-cancer drugs with Wuxi Apptech

Office on the 5th floor of Munjeong-dong
/ Bio-laboratory Expansion

Changing the corporate name to Therapex

Completing the spinoff of Organoid Division

Joint research agreement with Elgen
Therapeutics on developing PROTAC agents

Embarking on build-up of new drug R&D pipeline

Moving the headquarter and R&D center
to Songpa Area with expanded capacity

Appointing Dr. Koo Lee as CEO

Joint research agreement with Yonsei University Severance Biomedical
Science Institute on developing new drugs for lung cancer patients

Founded Interpark Bioconvergence Corp.